Multi-Center Clinical Study to Evaluate the Coldplay CryoBalloon Focal Ablation System for the Treatment of Patients with Previously Untreated Dysplastic Barretts Epithelium (COLDPLAY 3)
A study for patients with untreated dysplastic Barrett's Epithelium using the Coldplay CryoBallon Focal Ablation System
Sponsor: C2 Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAQ3550
U.S. Govt. ID: NCT02249975
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: C2 Therapeutics is currently enrolling patients to participate in the Coldplay 3 clinical trial. Coldplay 3 is evaluating the effectiveness of the Coldplay CryoBalloon Focal Ablation System in patients with Barrett's esophagus who have not yet received treatment. Participants will undergo treatment with the Coldplay CryoBalloon Focal Ablation System and report their level of discomfort and difficulty swallowing during the first seven days after the procedure. Follow-up appointments for the first year after treatment will be conducted every 10 weeks until an endoscopic exam and biopsy reveal no Barrett's esophagus.
This study is closed
Investigator
Julian Abrams, MD
Do You Qualify?
Do you have Barrett's esophagus that is dysplastic (low-grade or high-grade)? Yes No
Have you had previous treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE